Sector News

PROMETIC LIFE SCIENCES’S “BUY” RATING REAFFIRMED AT PARADIGM CAPITAL (PLI)

September 29, 2015
Life sciences

ProMetic Life Sciences (TSE:PLI)‘s stock had its “buy” rating reiterated by analysts at Paradigm Capital in a research note issued to investors on Monday, StockTargetPrices.com reports. They presently have a C$3.75 price target on the stock. Paradigm Capital’s price objective would suggest a potential upside of 132.92% from the company’s current price.

In other ProMetic Life Sciences news, Director Kurt Stefan Victor Clulow bought 229,900 shares of ProMetic Life Sciences stock in a transaction that occurred on Thursday, July 2nd. The stock was purchased at an average price of C$2.32 per share, with a total value of C$533,184.08. Also, Director Simon Geoffrey Best bought 30,000 shares of ProMetic Life Sciences stock in a transaction that occurred on Tuesday, September 8th. The shares were acquired at an average cost of C$1.95 per share, with a total value of C$58,464.00.

PLI has been the subject of a number of other research reports. Scotiabank set a C$3.00 target price on shares of ProMetic Life Sciences and gave the stock an “outperform” rating in a report on Thursday, July 9th. Canaccord Genuity decreased their price target on shares of ProMetic Life Sciences to C$3.50 and set a “buy” rating on the stock in a research note on Monday, August 17th.

ProMetic Life Sciences (TSE:PLI) traded down 6.83% during mid-day trading on Monday, reaching $1.50. The company had a trading volume of 868,749 shares. The company’s 50-day moving average is $1.92 and its 200-day moving average is $2.30. ProMetic Life Sciences has a one year low of $1.40 and a one year high of $2.87. The stock’s market capitalization is $871.08 million.

ProMetic Life Sciences Inc. (TSE:PLI) is a Canada-based biopharmaceutical company. The Company offers solutions in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens. The Company operates through two segments: Therapeutics and Protein Technology. Therapeutics segment is a small molecule drug discovery business. It has lead compounds, namely PBI-4050 indicated for the treatment of fibrosis in patients with chronic kidney diseases and certain cancers, and the side effects associated with chemotherapy. Protein Technology segment contains the financial information of the activities, including BioTherapeutics, Bioseparation and Prion Capture/Pathogen Removal.

By Christopher T. Ellis

Source: The Market Business

comments closed

Related News

December 5, 2021

Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma

Life sciences

After more than two years of leading LEO Pharma through a major transformation and a change of capital structure in a volatile environment during the global pandemic, the Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company on November 30, 2021.

December 5, 2021

Lonza and Bioqube Ventures to scale biologics and small molecules

Life sciences

Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.

December 5, 2021

UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases

Life sciences

UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases. UCB will receive upfront payment, future milestone payments and net sales royalties.

Send this to a friend